Optimizing Polycythemia Vera Management Through a Collaborative Care Model Between Leukemia Oncologists and an Integrated Specialty Pharmacy.

Polycythemia vera (PV) is a chronic myeloproliferative neoplasm that requires long-term hematologic control and symptom monitoring. Despite advanced therapies and treatment guidelines, real-world adherence to therapeutic goals and routine symptom assessment remains inconsistent, particularly outside the academic setting. To optimize care, a pharmacist-led clinical support program was implemented at Levine Cancer Institute, a large regional hematologic malignancy center, in collaboration with the integrated institutional Atrium Health Specialty Pharmacy Service (SPS). This program aimed to standardize PV care system-wide by improving hematocrit (Hct) control and supporting symptom burden assessment via Myeloproliferative Neoplasm Symptom Assessment Form (MPN-10) scores. Through diagnosis code screening and identification of patients with Hct ≥ 45%, the SPS pharmacist team provided clinical reviews, pharmacotherapy recommendations, financial access support, and coordinated care, including dispensing medication and providing medication education. Interim analysis demonstrated improved identification of opportunities for optimization, with sustained provider engagement. This model highlights the opportunity for advanced practitioners, including pharmacists, to improve disease control and quality of life for patients with PV.